VIAL COX, MARIA CECILIA
Preferred name
VIAL COX, MARIA CECILIA
Main Affiliation
Email
mcvial@udd.cl
ORCID
0000-0002-0399-6144
Scopus Author ID
55553152400
56 results
Now showing 1 - 10 of 56
- Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - TGFβ links EBV to multisystem inflammatory syndrome in children(Molecular Signatures Database (MSigDB), 2025); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Characterization of the epidemiologic, pathologic, radiologic, and management profile of patients with gastrointestinal stromal tumors (GISTs): A 5-year Chilean experience(Elsevier BV, 2025-01) - Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Post-COVID-19 condition: a sex-based analysis of clinical and laboratory trends(2024); ; ; RIVIOTTA, AMY LISA3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, NPC1 as a Modulator of Disease Severity and Viral Entry of SARSCoV- 2<jats:sec> <jats:title /> <jats:p>The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.</jats:p> </jats:sec>2Scopus© Citations 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 3Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile(2022); ; ; <jats:p>Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.</jats:p>6Scopus© Citations 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multicenter Study to Determine the Immune Response to the Vaccine Against SARS COV-2, in Patients With Chronic Kidney Disease on Dialysis and Kidney Transplants(2022); ; ; 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus(2015); 2Scopus© Citations 71 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 2Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages(2024)5Scopus© Citations 4